Additionally, COX-2 promoter-driven luciferase activity was also tested in lung cancer cells cotransfected with COX-2 (−459/+9 promoter region)-luciferase plasmids following the transfection with Ku80 and siCBP or C646 treatment. Here, XRCC5 is linked to lung cancer.